Differing Membrane Interactions of Two Highly Similar Drug-Metabolizing Cytochrome P450 Isoforms: CYP 2C9 and CYP 2C19

被引:10
|
作者
Mustafa, Ghulam [1 ,2 ]
Nandekar, Prajwal P. [1 ,2 ]
Bruce, Neil J. [1 ]
Wade, Rebecca C. [1 ,2 ,3 ]
机构
[1] HITS, Mol & Cellular Modeling Grp, D-69118 Heidelberg, Germany
[2] Heidelberg Univ, Zentrum Mol Biol, DKFZ ZMBH Alliance, D-69120 Heidelberg, Germany
[3] Heidelberg Univ, Interdisciplinary Ctr Sci Comp IWR, D-69120 Heidelberg, Germany
关键词
cytochrome P450; isoform; membrane protein; protein-membrane interactions; enzyme substrate specificity; mutagenesis; molecular dynamics simulation; MICROSOMAL CYTOCHROME-P450; CLOPIDOGREL BIOACTIVATION; SUBSTRATE RECOGNITION; MOLECULAR-DYNAMICS; BINDING; IDENTIFICATION; RESIDUES; DETERMINANTS; MECHANISM; BILAYER;
D O I
10.3390/ijms20184328
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The human cytochrome P450 (CYP) 2C9 and 2C19 enzymes are two highly similar isoforms with key roles in drug metabolism. They are anchored to the endoplasmic reticulum membrane by their N-terminal transmembrane helix and interactions of their cytoplasmic globular domain with the membrane. However, their crystal structures were determined after N-terminal truncation and mutating residues in the globular domain that contact the membrane. Therefore, the CYP-membrane interactions are not structurally well-characterized and their dynamics and the influence of membrane interactions on CYP function are not well understood. We describe herein the modeling and simulation of CYP 2C9 and CYP 2C19 in a phospholipid bilayer. The simulations revealed that, despite high sequence conservation, the small sequence and structural differences between the two isoforms altered the interactions and orientations of the CYPs in the membrane bilayer. We identified residues (including K72, P73, and I99 in CYP 2C9 and E72, R73, and H99 in CYP 2C19) at the protein-membrane interface that contribute not only to the differing orientations adopted by the two isoforms in the membrane, but also to their differing substrate specificities by affecting the substrate access tunnels. Our findings provide a mechanistic interpretation of experimentally observed effects of mutagenesis on substrate selectivity.
引用
收藏
页数:23
相关论文
共 50 条
  • [1] Development of Rapid Genotyping Methods for Single Nucleotide Polymorphisms of Cytochrome P450 2C9 (CYP2C9) and Cytochrome P450 2C19 (CYP2C19) and Their Clinical Application in Pediatric Patients with Epilepsy
    Yamamoto, Yoshiaki
    Takahashi, Yukitoshi
    Nishimura, Shigeko
    Ikumi, Yasuhiro
    Mishima, Nobuyuki
    Kagawa, Yoshiyuki
    YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN, 2011, 131 (05): : 809 - 815
  • [2] Variability in human drug metabolizing cytochrome P450 CYP2C9, CYP2C19 and CYP3A5 activities caused by genetic variations in cytochrome P450 oxidoreductase
    Velazquez, Maria Natalia Rojas
    Parween, Shaheena
    Udhane, Sameer S.
    Pandey, Amit, V
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2019, 515 (01) : 133 - 138
  • [3] The cytochrome P450 (CYP) 2C9/2C19 but not the ABCB1 genetic polymorphism predicts liver CYP3A4 induction by phenytoin
    Chhun, S.
    Verstuyft, C.
    Padoin, N.
    Simoneau, G.
    Becquemont, L.
    Bergmann, J. F.
    Mouly, S.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2007, 21 : 73 - 73
  • [4] Cytochrome P450 2C9 (CYP2C9) polymorphisms in Chinese Li population
    Ding, Yipeng
    Yang, Danlei
    Zhou, Long
    He, Ping
    Yao, Jinjian
    Xie, Pingdong
    Lin, Daobo
    Sun, Dingwei
    Sun, Pei
    Li, Quanni
    Geng, Tingting
    Jin, Tianbo
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2015, 8 (11): : 21024 - 21033
  • [5] Oesophageal cancer proliferation is mediated by cytochrome P450 2C9 (CYP2C9)
    Dizdar, L.
    Schmelzle, M.
    Wolters, J.
    Lindenlauf, N.
    Baldus, S. E.
    Topp, S. A.
    Esch, J. Schulte Am, II
    Eisenberger, C. F.
    Stoecklein, N. H.
    Knoefel, W. T.
    EJC SUPPLEMENTS, 2010, 8 (05): : 134 - 134
  • [6] Esophageal cancer proliferation is mediated by cytochrome P450 2C9 (CYP2C9)
    Schmelzle, Moritz
    Dizdar, Levent
    Matthaei, Hanno
    Baldus, Stephan E.
    Wolters, Judith
    Lindenlauf, Nina
    Bruns, Ingmar
    Cadeddu, Ron-Patrick
    Kroepil, Feride
    Topp, Stefan A.
    Esch, Jan Schulte Am, II
    Eisenberger, Claus F.
    Knoefel, Wolfram T.
    Stoecklein, Nikolas H.
    PROSTAGLANDINS & OTHER LIPID MEDIATORS, 2011, 94 (1-2) : 25 - 33
  • [7] Cytochrome P450 2C9-CYP2C9
    Van Booven, Derek
    Marsh, Sharon
    McLeod, Howard
    Carrillo, Michelle Whirl
    Sangkuhl, Katrin
    Klein, Teri E.
    Altman, Russ B.
    PHARMACOGENETICS AND GENOMICS, 2010, 20 (04): : 277 - 281
  • [8] In Vitro Functional Characterisation of Cytochrome P450 (CYP) 2C19 Allelic Variants CYP2C19*23 and CYP2C19*24
    Pui Shen Lau
    Kenny Voon Gah Leong
    Chin Eng Ong
    Amelia Nathania Hui Min Dong
    Yan Pan
    Biochemical Genetics, 2017, 55 : 48 - 62
  • [9] In Vitro Functional Characterisation of Cytochrome P450 (CYP) 2C19 Allelic Variants CYP2C19*23 and CYP2C19*24
    Lau, Pui Shen
    Leong, Kenny Voon Gah
    Ong, Chin Eng
    Dong, Amelia Nathania Hui Min
    Pan, Yan
    BIOCHEMICAL GENETICS, 2017, 55 (01) : 48 - 62
  • [10] The Structure of Human Cytochrome P450 2C19: Active site differences between P450s 2C19 and 2C9
    Reynald, Rosamund L.
    Sansen, Stefaan
    Stout, C. David
    Johnson, Eric F.
    FASEB JOURNAL, 2008, 22